RAMAT GAN, ISRAEL, March 20, 2026 (GLOBE NEWSWIRE) — XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), introduced lately that it plans to switch the ratio of its American Depositary Stocks (“ADSs”) to its odd stocks, par cost NIS0.1 in step with percentage (the “ADS Ratio”), from the present ADS Ratio of 1 (1) ADS to at least one hundred (100) odd stocks, to a brand new ADS Ratio of 1 (1) ADS to 400 (400) odd stocks (the “ADS Ratio Change”). The Corporate anticipates that the ADS Ratio Alternate might be efficient on March 25, 2026 (the “Effective Date”).
For the Corporate’s ADS holders, the trade within the ADS Ratio may have the similar impact as a one-for-four opposite ADS cut up. At the Efficient Date, registered holders of corporate ADSs held in certificated shape might be required on a compulsory foundation to give up their certificated ADSs to the depositary financial institution for cancellation and can obtain one (1) new ADS in trade for each and every 4 (4) current ADSs then-held. Holders of uncertificated ADSs within the Direct Registration Gadget (“DRS”) and in The Depository Agree with Corporate (“DTC”) may have their ADSs routinely exchanged and don’t need to take any motion. The trade of each and every 4 current ADSs for one (1) new ADS will happen routinely, with current ADSs being cancelled and new ADSs being issued via the depositary financial institution at the Efficient Date.
XTL’s ADSs will proceed to be traded below the ticker image “XTLB” at the Nasdaq Capital Marketplace. No charges might be charged to ADS holders, for each certificated or uncertificated ADSs, in reference to the trade of current ADSs for brand new ADSs.
No fractional new ADSs might be issued in reference to the trade within the ADS Ratio. As a substitute, fractional entitlements to new ADSs might be aggregated and bought via the depositary financial institution and the online money proceeds from the sale of the fractional ADS entitlements (after deduction of charges, taxes and bills) might be dispensed to the appropriate ADS holders via the depositary financial institution. The ADS Ratio Alternate will haven’t any have an effect on on XTL’s underlying odd stocks, and no odd stocks might be issued or cancelled in reference to the ADS Ratio Alternate.
Because of the trade within the ADS Ratio, XTL’s ADS buying and selling value is anticipated to extend proportionally, even if the Corporate can provide no assurance that the ADS buying and selling value after the ADS Ratio Alternate might be equivalent to or more than 4 occasions the buying and selling value in step with ADS sooner than the trade.
About XTL Biopharmaceuticals Ltd.
XTL is an IP Portfolio corporate that holds an IP portfolio together with hCDR1 for Lupus (SLE) and Sjögren’s Syndrome (SS) that the corporate sublicenses. The corporate actively pursues strategic collaborations and acquisitions to amplify its healing portfolio into high-value illness spaces.
XTL trades at the Nasdaq Capital Marketplace (NASDAQ: XTLB) and Tel Aviv Inventory Trade (TASE: XTLB.TA).
Cautionary Notice Referring to Ahead-Taking a look Statements
This communique accommodates forward-looking statements inside the which means of Segment 27A of the Securities Act of 1933, as amended, and Segment 21E of the Securities Trade Act of 1934, as amended. Any statements contained on this communique that aren’t statements of historic reality is also deemed forward-looking statements. Phrases reminiscent of “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and equivalent expressions are supposed to spot such forward-looking statements. All forward-looking statements contain important dangers and uncertainties that would motive exact effects to vary materially from the ones expressed or implied within the forward-looking statements, lots of which might be usually outdoor the keep watch over of the Corporate and are tough to are expecting. Examples of such dangers and uncertainties come with, however aren’t restricted to (i) whether or not to the Corporate will be capable to obtain sub-licensing charges with regards to its Hcdr1 highbrow belongings, (ii) the Corporate’s skill to effectively organize and combine joint ventures, acquisitions of companies, answers or applied sciences; (iii) unanticipated working prices, transaction prices and exact or contingent liabilities; (iv) the facility to draw and retain certified staff and key workforce; (v) antagonistic results of greater festival at the Corporate’s long term industry; (vi) the Corporate’s skill to give protection to its highbrow belongings; and (viii) native, business and normal industry and financial stipulations. Further elements that would motive exact effects to vary materially from the ones expressed or implied within the forward-looking statements can also be present in the latest annual document on Shape 20-F and present experiences on Shape 6-Okay filed via the Corporate with the Securities and Trade Fee. The Corporate anticipates that next occasions and tendencies would possibly motive its plans, intentions and expectancies to switch. The Corporate assumes no legal responsibility, and it in particular disclaims any purpose or legal responsibility, to replace any forward-looking statements, whether or not on account of new data, long term occasions or differently, aside from as expressly required via legislation. Ahead-looking statements discuss simplest as of the date they’re made and must now not be relied upon as representing the Corporate’s plans and expectancies as of any next date.
For additional data, please touch:
